Intent to sole source for BEST 1 Bridge Contract to Acumen LLC

Closed Special Notice Posted

Solicitation number
FDAINTENTTOSOLESOURCEBRIDGECONTRACTBEST1
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

NAICS code
541 Professional, Scientific, and Technical Services
PSC
B537 Special Studies/Analysis- Medical/Health
Place of performance
Silver Spring, Maryland 20993, United States
Points of contact

Notice details come from SAM.gov. Updated .

About this opportunity

The Food and Drug Administration (FDA) Office of Acquisition and Grant Services published a Special Notice on April 17, 2026, announcing its intent to award a sole source contract to Acumen LLC for the BEST 1 Bridge Contract. This special notice indicates that the FDA intends to continue an existing contractual relationship without pursuing competitive bidding. The opportunity falls under the Professional, Scientific, and Technical Services category (NAICS 541) and is classified as Special Studies/Analysis—Medical/Health (PSC B537). The stated purpose is to maintain critical continuity in the FDA's postmarket drug safety surveillance operations during a significant system transition. Interested parties have until May 1, 2026, to submit comments or submit a justification for why this work should not be sole sourced to Acumen LLC.

The bridge contract aims to ensure uninterrupted management and coordination of the BEST (Biologics Effectiveness and Safety) distributed data network while maintaining analytic capacity for safety surveillance across multiple data partners' databases. The contract is essential for fulfilling Congressional mandates under the FDA Amendments Act of 2007, the 21st Century Cures Act, and the Prescription Drug User Fee Act (PDUFA VII), as well as for completing in-progress surveillance projects that face significant regulatory timeline risks. Acumen LLC currently serves as the BEST Coordinating Center under existing IDIQ contract HHSF223201810020I and Task Order 75F40123F19005, with a current period of performance ending September 29, 2026, and an obligation of approximately $8,000,000. The sole source justification centers on the specialized expertise, established data partnerships, and mission-critical infrastructure that Acumen has developed under the current contract, which cannot be easily transferred without operational disruption. No set-aside has been used for this acquisition, and the bridge action represents a continuation of services rather than a new competitive procurement.

Notice text

Intent to Award a Sole Source Contract:           4/17/2026

The purpose of this acquisition is to:
1. Ensure uninterrupted management and coordination of activities across the BEST distributed data network and multiple data partners.
2. Maintain analytic capacity and capabilities to run surveillance queries, generate population-based estimates, detect safety signals, and conduct follow-up analysis on detected safety signals across millions of person-records included in the databases of multiple data partners.
3. Avoid costly delays and/or disruptions in mission-critical operations by completing in-progress surveillance projects and requirements by federal law – i.e., fulfilling Congressional mandates from the FDA Amendments Act 2007, 21st Centuries Cures Act, and the Prescription Drug User Fee Act (PDUFA VII) – during the transition to Sentinel 3.0. The ongoing PDUFA demonstration project faces significant risk of missing critical regulatory timelines without immediate contract continuity measures.

Coordination of the BEST Initiative is a major component of the FDA’s active postmarket safety surveillance capabilities and isanessential and necessary part of the agency’s implementation of the 21st Century Cures Act and the FDA Amendments Act of 2007 to use electronic healthcare data to evaluate the safety and effectiveness of biologics. The Coordinating Center plays a central role in executing the BEST Initiative’s objectives by maintaining the data and analytical infrastructure, expertise, and partnerships needed to monitor, refine and identify  safety signals, inform regulatory decisions, and fulfill FDA’s statutory obligations for biologic product surveillance. 

This bridge action is a continuation of services currently being performed under IDIQ: HHSF223201810020I and Task Order: HHSF223201810020I / 75F40123F19005, awarded to Acumen, LLC, which serves as the BEST Coordinating Center. The current period of performance ends on 9/29/2026 with approximately $8,000,000.00 obligated to date.
The incumbent was competitively awarded the contract. The follow-on acquisition is already in progress, but due to procurement timelines, a limited-duration extension is necessary to prevent a lapse in service.

A sole-source bridge is being pursued because any transition of work to a new entity at this stage would introduce delays and inefficiencies, and such transition would also risk impacting system processes necessary for fulfilling FDA statutory obligations. The incumbent’s business systems including data infrastructure, analytical capabilities, staffing, data coordination, and communication processes are deeply embedded in ongoing projects. Restarting or onboarding a new contractor would result in duplicative costs, loss of institutional knowledge, and disruption to time-sensitive public health surveillance deliverables.

This contract supports the coordinating center for the Biologics Effectiveness and Safety (BEST) Initiative. The coordinating center serves as the central hub for managing all aspects of the program, including the administration of task orders, coordination of data partners, project tracking, timeline oversight, and quality control across active surveillance activities. The coordinating center provides program management, technical infrastructure, analytical capabilities, scientific support, and administrative oversight to ensure the timely and consistent execution of surveillance studies conducted through separate contracts with data partners.

All work is governed by the Statement of Work and organized into infrastructure and study-related tasks. The coordinating center ensures continuity across projects, supports knowledge management, and maintains the technical infrastructure needed to support standardized data transformation and querying through the common data model, enabling timely and efficient delivery of safety surveillance outputs to meet CBER’s regulatory needs.

The 12 month bridge contract is required to ensure effective continuity of operations to protect Public Health from 9/30/2026 – 09/29/2027 for a total contract value approximately of $6M.

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity